Valbiotis Announces its Combined Shareholders General Meeting Will Be Held on May 5, 2022
19 Avril 2022 - 5:40PM
Business Wire
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / PME eligible)
(Paris:ALVAL), a Research and Development company committed to
scientific innovation for prevention and combating metabolic
diseases, announces its Combined Shareholders Meeting will be held
on May 5, 2022 and releases the procedures for making available and
consulting preparatory documents.
The Shareholders’ Meeting will be held at:
Espace ENCAN –Quai Louis Prunier –17000 La
Rochelle May 5, 2022, at 5.00 pm
The Shareholders who wish to attend the Shareholders’ Meeting
must hold an admission card and an identity document.
The means of taking part in the Shareholders’ Meeting and the
draft proposed resolutions were published in the Bulletin des
Annonces Légales Obligatoires (BALO) on March 28, 2022, in Issue
No. 37 (https://www.journal-officiel.gouv.fr).
The convening notice, including the agenda and the final
resolutions projects, as well as the modalities of participation
and vote at the General Meeting, was published on the Company
website and in the Bulletin des Annonces Légales Obligatoires
(BALO) on April 15, 2022, in Issue No. 45
(https://www.journal-officiel.gouv.fr).
All the documents related to the May 5, 2022 Combined General
Meeting, in accordance with Article R.22-10-23 of the French
Commercial Code, can be accessed on the Valbiotis website at the
following section:
https://www.valbiotis.com/en/general-assemblies/). They will also
be available at the Company headquarters or by mail at:
contact@valbiotis.com.
The documents and information concerning the Shareholders’
Meeting will be made available to shareholders as provided by
applicable regulations.
In the evolving context of the COVID-19 epidemic and the fight
against its spread, the procedures for holding and participating in
this Assembly may have to evolve according to health, regulatory
and legal imperatives. Shareholders are invited to regularly
consult the section dedicated to the 2022 General Meeting on the
company’s website:
https://www.valbiotis.com/en/general-assemblies/, which could be
updated to specify the definitive modalities of participation in
the Meeting, according to the aforementioned imperatives.
About Valbiotis Valbiotis is a Research & Development
company committed to scientific innovation for preventing and
combating metabolic and cardiovascular diseases in response to
unmet medical needs. Valbiotis has adopted an innovative approach,
aiming to revolutionize healthcare by developing a new class of
health nutrition products designed to reduce the risk of major
metabolic diseases, relying on a multi-target strategy enabled by
the use of plant-based terrestrial and marine resources. Its
products are intended to be licensed to players in the health
sector. Created at the beginning of 2014 in La Rochelle, the
Company has forged numerous partnerships with leading academic
centers. The Company has established three sites in France –
Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in
Quebec City (Canada). Valbiotis is a member of the "BPI Excellence"
network and has been recognized as an "Innovative Company" by the
BPI label. Valbiotis has also been awarded "Young Innovative
Company" status and has received major financial support from the
European Union for its research programs via the European Regional
Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit:
www.valbiotis.com
Name: Valbiotis ISIN code: FR0013254851 Mnemonic code: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about
Valbiotis’ objectives. Valbiotis considers that these projections
are based on rational hypotheses and the information available to
Valbiotis at the present time. However, in no way does this
constitute a guarantee of future performance, and these projections
may be affected by changes in economic conditions and financial
markets, as well as certain risks and uncertainties, including
those described in the Valbiotis Universal Registration Document
approved by the French Financial Markets Regulator (AMF) on July
27, 2021 (application number R 21-039). This document is available
on the Company’s website (www.valbiotis.com). This press release
and the information it contains do not constitute an offer to sell
or subscribe, or a solicitation to purchase or subscribe to
Valbiotis’ shares or financial securities in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220419005603/en/
Corporate communication / Valbiotis Carole ROCHER / Marc
DELAUNAY +33 5 46 28 62 58 media@valbiotis.com
Financial communiation / Actifin Stéphane RUIZ +33 1 56 88 11 14
sruiz@actifin.fr
Valbiotis (EU:ALVAL)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Valbiotis (EU:ALVAL)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024